A safety and pharmacokinetic study of intravenous natalizumab in patients with MS
- 1 March 1999
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 52 (5), 1072
- https://doi.org/10.1212/wnl.52.5.1072
Abstract
Article abstract A phase 1, randomized, placebo-controlled, five-level dose escalation safety and tolerability and pharmacokinetic study of a single IV dose of natalizumab was performed. Doses of 0.03 to 3.0 mg/kg natalizumab or placebo were studied in 28 stable relapsing-remitting or secondary-progressive MS. All doses were safe and well tolerated in MS. Serum concentrations of natalizumab are detectable for 3 to 8 weeks after a single 1- or 3-mg/kg IV dose and justify controlled efficacy studies.Keywords
This publication has 9 references indexed in Scilit:
- A monoclonal antibody to α4 integrin suppresses and reverses active experimental allergic encephalomyelitisJournal of Neuroimmunology, 1995
- Leukocyte-endothelial adhesion moleculesBlood, 1994
- Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine–enhancing magnetic resonance imaging lesionsAnnals of Neurology, 1993
- Multiple sclerosis: Remyelination of nascent lesions: Remyelination of nascent lesionsAnnals of Neurology, 1993
- Prevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrinNature, 1992
- Serial gadolinium‐enhanced MRI in relapsing/remitting multiple sclerosis of varying disease durationNeurology, 1992
- Serial gadolinium‐enhanced magnetic resonance imaging scans in patients with early, relapsing‐remitting multiple sclerosis: Implications for clinical trials and natural historyAnnals of Neurology, 1991
- Major differences in the dynamics of primary and secondary progressive multiple sclerosisAnnals of Neurology, 1991
- New diagnostic criteria for multiple sclerosis: Guidelines for research protocolsAnnals of Neurology, 1983